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Purpose. Besides being widely used in cosmetics, reti-
noids are potent therapeutic agents used topically and 
systemically as anti-acne agents. The aim of this study 
was to predict with the use of MetaSite the skin metabo-
lism of selected retinoids employed in treatment of skin 
disorders and found in cosmeceuticals. The following 
compounds were studied: retinol, retinaldehyde, retinoic 
acid, retinyl acetate, retinyl palmitate, acitretin, etreti-
nate, adapalene and bexarotene. Methods. MetaSite, 
Molecular Discovery Ltd. is a computational model that 
enables prediction of cytochrome P450-dependant me-
tabolism. This software indicates atoms in the molecule 
structure that are mostly vulnerable to metabolic chang-
es and predicts the metabolite structures. Results. Meta-
Site indicated that retinol and retinal metabolites were 
obtained through hydroxylation of the methyl group 
located in the position 3 of the aliphatic chain, whereas 
retinoic acid biotransformation would occur principally 
in the carbon atom situated in the position 4 in the cy-
clohexene ring. In acitretin molecule, carbon atom of the 
methoxy group attached to the benzene ring displayed 
the highest probability of biotransformation. In etreti-
nate, metabolic reactions would occur principally on the 
carbon atom of the final ethyl group of the molecule. 
Conclusions. MetaSite metabolism predictions for reti-
noic acid, acitretin, etretinate, adapalene and bexarotene 
were in agreement with experimental findings. In case 
of compounds being converted by catalysts other than 
cytochrome P450 enzymes, the primary metabolites pre-
dicted by MetaSite differ from those reported previously. 
In conclusion, MetaSite is a useful tool that can aid iden-
tification of the major metabolites of compounds being 
administered topically.
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INTRODUCTION
The term retinoids refers to vitamin A (retinol, ROL) 
and its natural and synthetic derivatives. Through inter-
actions with specific cellular and nucleic acid receptors 
this group of compounds influences many vital biolog-
ical processes such as regulation of skin function and 
neuronal development (Sorg et al., 1999; Hellmann-Re-
gen et al., 2013). Besides being widely used in cosmetic 
products, retinoids are potent therapeutic agents used 
topically and systemically as highly effective anti-acne 
agents. A hallmark of endogenous retinoid signaling in 
the skin is its local, paracrine, homeostatic regulation, in 
which local retinoic acid (RA) metabolism plays an es-
sential role (Baron et al., 2008).
It was demonstrated previously that retinoids antago-
nize reduced cell growth and increased collagen-degrad-
ing matrix metalloproteinases in naturally aged human 
skin and regulate the keratinization process (Varani et al., 
1990; Baron et al., 2005; Jean et al., 2011). Additional-
ly, retinoids abolish sun-induced skin hyperpigmentation 
and are effective in treatment of the sun-damaged skin 
(Nyirady et al., 2001; Draelos, 2005; Kang et al., 2005; 
Mukherjee et al., 2006; Sorg et al., 2006; Serri & Ioriz-
zo, 2008; Kircik, 2012; Hubbard et al., 2014). Moreover, 
these compounds stimulate the production of colla-
gen and elastin in the dermis. This is achieved through 
transformation of less active fibroblasts into cells that 
produce large amounts of collagen (Varani et al., 2000; 
Rossetti et al., 2011). The increase in the number and ac-
tivity of fibroblasts improves skin firmness, elasticity and 
hydration. Additionally, retinoids may be also classified 
as anti-inflammatory agents, inhibiting e.g. microglial ac-
tivation (Hellmann-Regen et al., 2013).
Retinoids are divided into four categories based on 
their chemical structure. First generation includes the 
natural, nonaromatic compounds. Retinoids belonging to 
this group such as ROL, RA and isotretinoin are used 
in the treatment of acne. The second generation of ret-
inoids consists of monoaromatic compounds that are 
synthetic vitamin A analogs. This group of compounds 
is useful in the pharmacotherapy of severe forms of pso-
riasis and keratinization disorders (Ianhez et al., 2013). 
In this category there are acitretin and etretinate (Sark-
ar et al., 2013). The third generation such as adapalene, 
bexarotene and tazarotene are polyaromatic retinoid 
derivatives and are used in the therapy of plaque pso-
riasis. Finally, fourth generation of retinoids comprises 
pyranones such as seletinoid G (Blomhoff & Blomhoff, 
2006; Mukherjee et al., 2006; Brun et al., 2013). Seletinoid 
G is a novel synthetic retinoid that was found to repair 
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altered connective tissue and to inhibit UV-induced col-
lagen deficiency when tested in aged human skin in vivo 
(Kim et al., 2005).
With respect to their skin action, retinoids can be 
divided into three categories i.e. topically administered 
retinoids registered as drugs (e.g. tretinoin, isotretinoin, 
alitretinoin, tazarotene and adapalene); systemic retinoids 
that are not available for topical treatment (e.g. acitretin 
and etretinate); and compounds incorporated into skin 
products (e.g. ROL, retinaldehyde (RAL) and retinyl es-
ters (REs)) (Babamiri & Nassab, 2010; Sarkar et al., 2013; 
Hubbard et al., 2014).
As the skin is the active site of retinoid metabolism, 
the aim of this study was to predict the local (skin) me-
tabolism of selected retinoids, employed for topical and 
systemic treatment of various skin disorders and found 
in cosmeceuticals, by using the MetaSite computation-
al technique. The following compounds were studied: 
ROL, RAL, RA, retinyl acetate, retinyl palmitate, acitre-
tin, etretinate, adapalene and bexarotene. Subsequently, 
the results obtained were compared to experimental ob-
servations in order to evaluate the utility of MetaSite in 
drug discovery metabolite identification studies.
MATERIALS AND METHODS
MetaSite, Molecular Discovery Ltd., v.3.1.1.2 is a 
computational model that enables prediction of the 
cytochrome P450 (CYP450)-dependent metabolism in 
phase I biotransformations. The main idea of Meta-
Site methodology is analysis of the protein-ligand in-
teractions. This software is primarily designed to in-
dicate atoms in the molecular structure that are the 
most vulnerable to metabolic changes due to the 
cytochrome action. These regions are known as the 
sites of metabolism (SOM) or hot spots. Validation 
procedures have proved that in 85% of the analyzed 
structures the indicated metabolic sites agreed in top 
three rankings with experimental data (Cruciani et al., 
2005; Molecular Discovery Ltd., 2014). Additionally, 
the method predicts atoms in the molecular struc-
ture that contribute to a particular SOM. Another im-
portant MetaSite advantage is prediction of chemical 
structures of the most likely metabolites (Zhou et al., 
2006).
The probability of a specific atom i to be a site of 
metabolism catalyzed by the heme moiety of CYP450 
depends on several factors, namely the accessibility of 
atom i towards the heme (indicated as Ei); the chemical 
reactivity of atom i in the specific reaction mechanism 
(described as Ri) and the relative probability of a reac-
tion mechanism under consideration that occurs (called 
Mi). Thus, the probability function (PSMi) for a specific 
atom i can be defined by the following equation: PSMi = 
Ei x Ri x Mi (Cruciani et al., 2005; Molecular Discovery 
Ltd., 2014). Lastly, the final ranking for potential meta-
bolic sites is obtained and the probability score (PS) is 
given.
It is noteworthy that in silico tools such as Meta-
Site that predict the metabolism of xenobiotics may 
be useful in the assessment of a compound’s meta-
bolic stability and therefore, may enable the synthesis 
of new compounds with improved metabolic profile. 
The metabolism prediction is usually performed for 
the most prevalent human CYP450 isoforms such as 
1A2, 2C9, 2C19, 2D6 and 3A4. Thus, a comprehen-
sive prediction for specific organs such as liver, skin 
and brain is provided.
RESULTS
The MetaSite metabolic predictions for all analyzed 
compounds are presented in Fig. 1. The top three sites 
of metabolism were presented for each tested com-
pound.
In case of both ROL (Fig. 1A) and RAL (Fig. 1B) 
MetaSite predicted that the carbon atom of the methyl 
group located in position 3 of the aliphatic chain was 
most likely metabolized by the skin (retinol PS of 12.5; 
RAL PS of 10.5). The software calculations predicted 
that the primary ROL and RAL metabolites (M1) were 
obtained through the hydroxylation at the methyl group 
located in this particular position. M2 and M3 of RAL 
and M3 of ROL were the products of aliphatic carbon-
ylation that lead to the formation of carbonyl (ketone) 
derivatives of ROL and RAL. Finally, M2 of ROL is a 
derivative formed via dehydrogenation with vinyl substit-
uent in ROL aliphatic chain.
The prediction of RA (Fig. 1C) metabolism showed 
that its biotransformation would occur principally at the 
carbon atom located in position 4 in cyclohexene ring 
(PS of 6.7). The secondary SOM was a methyl substitu-
ent in positions 7 (PS of 6.1) and 3 (PS of 5.8) of the 
aliphatic chain. That skin enzymes would catalyze ali-
phatic hydroxylation of RA was the most probable bio-
transformation pathway that produced three main RA 
metabolites such as 4-hydroxyretinoic acid (4-OH-RA) 
(M1), cyclohexa-1,3-diene derivative (M2) and 4-oxoreti-
noic acid (4-oxo-RA) (M3).
In retinyl acetate molecule (Fig. 1D) MetaSite indicat-
ed the carbon atom situated in position 4 in cyclohexene 
ring as the prime metabolic position (PS of 8.8), whereas 
the atoms located in positions 3 and 7 of the aliphat-
ic chain as the second and the third SOM (PS of 8.1 
and 7.9, respectively). The primary three retinyl acetate 
metabolites were generated through aliphatic hydroxyla-
tion leading to the formation of 4-hydroxy-(M1), 4-oxo- 
(M2), and cyclohexa-1,3-diene derivatives (M3) of retinyl 
acetate.
In case of retinyl palmitate (Fig. 1E) MetaSite gave the 
highest metabolism priority to the carbon atom in posi-
tion 15 located in the ester fragment derived from pal-
mitic acid (PS of 8.8), whereas the second and the third 
SOM were methyl groups in positions 3 and 7 of the 
aliphatic ester fragment derived from retinol (PS of 8.1 
and 7.9, respectively). The main metabolic reaction in-
dicated by the software was aliphatic hydroxylation that 
lead primarily to the formation of retinyl 15-hydroxypal-
mitate (M1). Additionally, M2 and M3 were the products 
of aliphatic hydroxylation and vinylic dehydrogenation at 
the methyl substituent located in position 3 of retinyl ali-
phatic fragment of the molecule.
Prediction of the metabolic fate of acitretin (Fig. 1F) 
showed that the carbon atom of methoxy group at-
tached to the benzene ring displayed the highest PS of 
biotransformation (10.1); next in the hierarchy was the 
carbon atom located at the methyl substituent in posi-
tion 7 of the aliphatic chain (PS of 6.4), and finally the 
carbon atom located in position 3 on benzene ring (PS 
of 5.4). The main metabolite of acitretin was generated 
through O-dealkylation within methoxy group substituted 
in a ring, whereas the other two metabolites possessed 
hydroxyl group or carbonyl at the methyl group in posi-
tion 7 of the aliphatic chain of acitretin.
The primary site of CYP attack predicted by MetaSite 
for etretinate (Fig. 1G) was at the carbon atom of the 
final ethyl group of the molecule, where biotransforma-
tion started with the PS of 13.3. Next in hierarchy was 
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Figure 1A–I. Plots of MetaSite predictions for sites of metabo-
lism of the analyzed compounds. 
The functional groups in compounds that most likely will be 
metabolized by skin tissue are marked: the darker the color the 
higher the probability score (PS) of metabolism to occur; M1–3 — 
metabolites. LogP values calculated using MetaSite are given in 
brackets. 
A F
B G
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E
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the methyl substituent carbon atom attached to the ben-
zene ring in position 6 (PS of 7.6) and carbon atom at 
the methyl group in position 7 of the aliphatic chain (PS 
of 6.3). Two primary metabolites of etretinate i.e. acitre-
tin and acetic acid were generated through O-dealkyla-
tion, whereas M3 was the product of dehydrogenation.
The software assigned the carbon atom of the meth-
oxy group located in position 4 of the phenyl ring in 
adapalene (Fig. 1H) as the most vulnerable to skin meta-
bolic changes (PS of 8.2). Further sites of metabolism 
were indicated within adamantyl moiety (PS of 5.8). In 
case of adapalene the first metabolic reaction was O-
dealkylation, whereas the next two were aliphatic hy-
droxylations. Due to metabolic biotransformation ada-
palene hydroxy metabolites or dealkylated products were 
formed.
The last compound tested was bexarotene, where cal-
culations indicated that its biotransformation (Fig. 1I) 
started at the carbon atom located in position 3 of the 
dihydronaphthalene ring (PS of 9.1). The carbon atom 
situated in position 7 of the same ring was indicated as 
the second SOM (PS of 4.8). Finally, carbon atoms of 
methyl groups attached to dihydronaphthalen in position 
5 were predicted as the third SOM (PS of 4.7). Aliphatic 
hydroxylation was the metabolic reaction that gave three 
main bexarotene metabolites, namely 6-hydroxy, 7-hy-
droxy and 5-hydroxymethyl-5-methyl- derivatives of bex-
arotene.
DISCUSSION
In silico models are useful tools to study metabolic fate 
of chemical compounds. In the present study we used 
MetaSite, a metabolism site prediction program, to pre-
dict CYP450-derived skin metabolites of selected reti-
noids used in the treatment of various skin conditions 
as well as found in skin care products. The compounds 
investigated were ROL, RAL, RA, retinyl acetate, retinyl 
palmitate, acitretin, etretinate, adapalene and bexarotene. 
The results obtained were compared to experimental ob-
servations in order to evaluate the utility of MetaSite in 
drug discovery metabolite identification studies.
It was demonstrated previously that under physiologi-
cal conditions RA is synthesized via the RDHs (retinol 
dehydrogenases)/RALDHs (retinal dehydrogenases) and 
metabolically inactivated via the CYP450 enzymes, espe-
cially 26A, 26B, but also by 1A2, 3A4, 2C8, 2C9 and 
2C19 (Roos et al., 1998; Blomhoff & Blomhoff, 2006; 
Oesch et al., 2007; Baron et al., 2008; von Lintig, 2012; 
Brun et al., 2013; Conaway et al., 2013). That is why pre-
dicting the metabolic fate of retinoids is of such great 
relevance.
MetaSite prediction of aliphatic hydroxylation and ali-
phatic carbonylation of RA as the most probable path-
ways of biotransformation proved to be accurate as it 
was reported previously that (4-OH-RA) and (4-oxo-
RA) are the most important RA metabolites. Both com-
pounds are removed from the cells more rapidly than 
the parent compound (Westin et al., 1993; Duell et al., 
1996; Sorg et al., 1999). It is noteworthy that MetaSite 
portrayed 3,4-didehydroretinoic acid as one of the most 
probable products of RA metabolism (Reynolds et al., 
1993).
Derivatives of ROL such as retinyl acetate and reti-
nyl palmitate are characterized by increased chemical sta-
bility as compared to ROL. Therefore, REs are widely 
used in cosmetics. Upon presentation of REs to Meta-
Site, the software indicated aliphatic hydroxylation of 
both molecules as the most likely route of metabolism 
resulting in appropriate hydroxy derivatives. Additional 
retinyl acetate metabolites were cyclohexa-1,3-diene- and 
4-oxoretinyl acetate, whereas retinyl palmitate in silico 
biotransformation gave metabolites with hydroxy group 
substituted in the cyclohexene ring or in the aliphatic 
chain. To the best of our knowledge, no such metabo-
lites have been observed in vivo/ in vitro as REs primar-
ily metabolic transformation is hydrolysis to ROL (Roos 
et al., 1998; Sorg et al., 2006). This reaction is catalyzed 
by retinyl ester hydrolases (REHs) (Törmä & Vahlquist, 
1990; O’Byrne & Blaner, 2013). It was demonstrated 
that in human skin, 44% of the absorbed retinyl palmi-
tate is hydrolyzed to ROL (Boehnlein et al., 1994).
Topical ROL is a precursor of cutaneous RAL as 
RDHs and retinal reductase (RALR) enable the revers-
ible conversion of ROL and RAL. Next, RAL is ir-
reversibly oxidized into RA in reactions catalyzed by 
RALDH and CYP450 enzymes (Kurlandsky et al., 1994; 
Roos et al., 1998; O’Byrne & Blaner, 2013). Then, after 
the conversion to appropriate REs, ROL is stored in the 
skin (Sorg et al., 2006). This reaction is possible due to 
the presence of lecithin: retinol-acyltransferase (LRAT) 
and acyl CoA: acyl-transferase (ARAT) (Kurlandsky et 
al., 1996; O’Byrne & Blaner, 2013). Subsequently, REH 
catalyzes the hydrolysis of REs to ROL, thus providing 
the new pool of active ROL. On the other hand, topi-
cal RAL is mostly biotransformed into ROL and REs, 
and only a small amount of retinal undergoes oxidation 
to RA. CYP450 enzymes are involved in RAL conver-
sion to 4-hydroxyretinal (Siegenthaler et al., 1990; Sorg 
et al., 1999; Mukherjee et al., 2006). According to Meta-
Site, both ROL and RAL molecules undergo primarily 
aliphatic hydroxylation to generate appropriate hydroxy 
metabolites. Additionally, the software indicated carbonyl 
(ketone) derivatives of ROL and RAL.
With reference to the second generation of retinoids, 
our in silico tool indicated that aromatic retinoid acitre-
tin metabolic fate was related to O-dealkylation that lead 
to the formation of appropriate hydroxy metabolites. In 
silico metabolism indicated also the formation of carbonyl 
metabolites of acitretin. At the same time, MetaSite sug-
gested that acitretin is the primary metabolite of etreti-
nate. Such a metabolic pathway is a valuable result as 
etretinate is indeed converted to acitretin and may serve 
as a prodrug for acitretin (Millikan, 2005; Sarkar et al., 
2013).
In case of the third generation of retinoids, ada-
palene in silico biotransformation gave appropriate hy-
droxy metabolites or dealkylated products of the par-
ent compound. Adapalene is a derivative of naphthoic 
acid, which has a non-steroidal anti-inflammatory agent 
(NSAID)-like structure, but retinoid-like features. It is 
also worthwhile noting that in case of topically applied 
adapalene its metabolic fate is actually unknown and its 
metabolites were not identified. It was stated, however, 
that its biotransformation involves primarily O-demethyl-
ation and hydroxylation of the methoxy benzene ring of 
adapalene and this is consistent with our in silico predic-
tion (Ayala, 2006). Finally, 6-hydroxybexarotene was pre-
dicted as the most probable metabolite of bexarotene. 
This was confirmed experimentally when bexarotene me-
tabolism was studied using animal liver slices and pooled 
human microsomes (Howell et al., 2001).
In case of all compounds tested, except for retinyl 
palmitate, the primary metabolite’s logP values were 
lower than those of the parent compound. This is with 
accordance with general rule that catabolism of chemical 
compounds generates polar water-soluble metabolites.
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It is rather due to the pharmacodynamic effects (se-
vere side effects) that retinoid’s topical application is pre-
ferred over systemic application. Pharmacokinetic effects 
are always an issue with retinoids, which massively in-
duce their own metabolism via upregulation of CYP450 
enzymes. Therefore, a full view of the metabolism of 
topically applied compounds is of great importance. Ob-
viously, in vitro and in vivo experiments are irreplaceable, 
however, there is a need for the use of in silico predic-
tions to get answers on a given compound’s metabolism. 
The main advantages of in silico models vs. in vitro and 
in vivo experiments are their simplicity, relatively low cost 
and the possibility to make fast predictions for a large 
group of chemical compounds even before the synthesis 
of a particular compound. Thus, compounds presenting 
an unfavorable (e.g. toxic) metabolic profile would not 
be synthesized. On the other hand, the main drawbacks 
of in silico methods with respect to in vitro and in vivo me-
tabolism models are related to the fact that the expert 
systems are based on the combination of metabolic rules 
appropriate for various mammalian models (species), 
consequently in silico models may not reflect species spe-
cific pathways and reliable metabolism prediction (Kirch-
mair et al., 2012). Additionally, the software tools tend 
to generate a large amount of metabolites which may 
hinder the classification and prioritization of predictions 
(Langowski & Long, 2002; Kirchmair et al., 2012).
After analyzing retinoid metabolism data collected by 
using MetaSite it can be concluded that for some com-
pounds such as RA, acitretin, etretinate, adapalene and 
bexarotene the predictions were very accurate and me-
tabolites indicated by the software are in agreement with 
experimental findings. For other compounds, namely 
ROL, RAL, retinyl acetate and retinyl palmitate a dis-
crepancy existed between in silico prediction and data 
demonstrated in the literature that is based on in vitro 
and in vivo models. Such difference is attributed to the 
fact that MetaSite applies only to specific enzymes such 
as those belonging to CYP450 family, that are the most 
important enzymes responsible for xenobiotics metabo-
lism in human skin (Oesch et al., 2007; Svensson, 2009). 
Therefore, in case of retinoids being converted by bio-
logical catalysts other than CYP450 enzymes or by CYP 
enzymes that are not part of the MetaSite database, 
such as e.g. CYP26A1 which is responsible for the me-
tabolism of RA in the skin cells, the primary metabo-
lites predicted by software differ from those reported in 
the literature. In order to obtain a more comprehensive 
view of a given compound’s metabolism, several specific 
models present in various software should be combined. 
In conclusion, MetaSite predictive expert system is a 
very useful tool that can aid the identification of major 
metabolites of compounds being administered topically.
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